Drugs / Zemprocitinib
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 2 met primary | ||||||
| Phase 2 | NCT06085521 | Jan 2022 → Jun 2023 | atopic eczema | Lynk Pharmaceuticals Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT06085534 | Jan → Dec 2022 | ankylosing spondylitis | Lynk Pharmaceuticals Co., Ltd | Completed | Met primary |
| Phase 2 | NCT06099535 | Nov 2021 → Dec 2022 | rheumatoid arthritis | Lynk Pharmaceuticals Co., Ltd | Completed | Met primary |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT07237568 | Aug 2025 → Nov 2026 expected | ankylosing spondylitis | Lynk Pharmaceuticals Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT06277245 | Feb 2024 → Apr 2025 | atopic eczema | Lynk Pharmaceuticals Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT06276998 | Dec 2023 → Aug 2025 overdue | rheumatoid arthritis | Lynk Pharmaceuticals Co., Ltd | Active not recruiting | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-01-16 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Results Simcere Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis simcere.com ↗
Jan. 12, 2026， Simcere Pharmaceutical Group (2096.HK) announced positive topline results from a Phase III clinical trial evaluating zemprocitinib (LNK01001) in patients with moderate to severe active rheumatoid arthritis (RA). |
| 2023-08-23 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Results Positive Results from Phase II Clinical Study of JAK1 Inhibitor for AS Treatment Jointly Introduced by Simcere Pharmaceutical and Lynk Pharmaceuticals simcere.com ↗
On Aug. 23, 2023, Simcere Pharmaceutical Co., Ltd. (“Simcere”) and Lynk Pharmaceuticals (Hangzhou) Co., Ltd. ( “Lynk Pharmaceuticals”) announced positive topline data a Phase II clinical trial of LNK01001 for the treatment of ankylosing spondylitis (“AS”). |
| 2023-05-16 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Results Positive Clinical Results from Phase II Achieved for the Innovative Drug of Novel JAK1 Inhibitor Cooperatively Introduced by Simcere Pharmaceutical and Lynk Pharmaceuticals simcere.com ↗ |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-01-16 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Simcere Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis simcere.com ↗ |
| 2023-12-20 | Jiangsu Simcere Pharmaceutical Co., Ltd. | LNK01001 dosed to first patient for treatment of rheumatoid arthritis in the Phase III clinical study simcere.com ↗ |
| 2023-08-23 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Positive Results from Phase II Clinical Study of JAK1 Inhibitor for AS Treatment Jointly Introduced by Simcere Pharmaceutical and Lynk Pharmaceuticals simcere.com ↗ |
| 2023-05-16 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Positive Clinical Results from Phase II Achieved for the Innovative Drug of Novel JAK1 Inhibitor Cooperatively Introduced by Simcere Pharmaceutical and Lynk Pharmaceuticals simcere.com ↗ |
| 2022-03-18 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Simcere and Lynk Pharmaceuticals Announced Strategic Commercialization Partnership upon Novel JAK1 Inhibitor LNK01001 simcere.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zemprocitinib | “LNK01001 (Zemprocitinib)” NCT06276998 ↗ |
| Known as | LNK01001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06099535 ↗ |
| Modality | Small molecule | — CHEMBL6068039 ↗ |
| Route | Oral | “Capsules taken orally” NCT06085521 ↗ |